News headlines about Benitec Biopharma (NASDAQ:BNTC) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Benitec Biopharma earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.7903584592237 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Benitec Biopharma (NASDAQ BNTC) traded down $0.06 during trading on Tuesday, reaching $3.25. 10,185 shares of the company’s stock were exchanged, compared to its average volume of 34,606. The firm has a market cap of $33.23, a price-to-earnings ratio of -5.00 and a beta of 3.75. Benitec Biopharma has a 52-week low of $1.85 and a 52-week high of $5.48.
Separately, ValuEngine lowered shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.
About Benitec Biopharma
Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.